Search

Withdrawn. Checked 2026-10-03. Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT Assessing the Efficacy of Anti-staphylo

Status unconfirmed. Checked 2026-10-03. The central aim of this trial is to investigate the safety and tolerability of Phage Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns susceptible to infection/o

Completed. Checked 2026-10-03. Oropharynx is the main source of pathogen microorganisms for the ventilator - associated pneumoniae. As known bacteriophages can eliminate different pathogen microorganisms or reduce a degree of a pathogen's c

Completed. Checked 2026-10-03. The BacterioPHAGE for Gastrointestinal Health-2 study is designed to determine if a commercial bacteriophage product can increase the survival and efficacy of probiotic bacteria that will be concurrently admin

Completed. Checked 2026-10-03. Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic ca

Unavailable. Checked 2026-10-03. Phage Treatment in Covid-19 Patients with Bacterial Co-Infections Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii,

Recruiting. Checked 2026-10-03. This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject. Phage Safety Cohort

Active, not recruiting. Checked 2026-10-03. The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil muc

Completed. Checked 2026-10-03. This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the s

Status unconfirmed. Checked 2026-10-03. The aim of this study is to determine the imputability of adverse events in patients who have had phage therapy for the treatment of their bone or joint or implant infection, in order to find out whet

Completed. Checked 2026-10-03. The purpose of study BMX-02-001 is to evaluate the safety, tolerability and feasibility of orally administered BX002-A to deliver viable bacteriophages to the gut. A Phase 1, Randomized, Single-blind, Placebo-

Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. Randomized Open Label, Parallel Group, Controlled Study to Evaluate the Safety and Surgery Spari

Completed. Checked 2026-10-03. This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers. A Double-Blind and Randomized Study to Determine the Safety and Tolerability of Multiple Do

Status unconfirmed. Checked 2026-10-03. This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aerugino

Completed. Checked 2026-10-03. This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load i

Terminated. Checked 2026-10-03. This is a phase 2b randomized trial designed to evaluate bacteriophage therapy in subjects with diabetic foot osteomyelitis. Phase 2b Randomized, Parallel, Double-blind, Placebo-Controlled, Repeat Dose, Multi

Active, not recruiting. Checked 2026-10-03. The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella ch

Completed. Checked 2026-10-03. Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic T

Withdrawn. Checked 2026-10-03. The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic de

Withdrawn. Checked 2026-10-03. This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (P